Lineage-specific restraint of pituitary gonadotroph cell adenoma growth

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Chesnokova, Vera ^a   Zonis, Svetlana ^a   Zhou, Cuiqi ^a   Ben Shlomo, Anat ^a   Wawrowsky, Kolja ^a   Toledano, Yoel ^a   Tong, Yunguang ^a,b,c   Kovacs, Kalman ^b   Scheithauer, Bernd ^c   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CELL PROTEIN; CLUSTERIN; PROTEIN FOXL2; PROTEIN P15; PROTEIN P16; PROTEIN P21; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; CLU PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FORKHEAD TRANSCRIPTION FACTOR; FOXL2 PROTEIN, HUMAN; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; GONADOTROPH ADENOMA; GONADOTROPIN SECRETING CELL; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HUMAN; HUMAN TISSUE; MOUSE; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; ONCOGENE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RNA INTERFERENCE; TRANSGENIC MOUSE; ANIMAL; BIOLOGICAL MODEL; CELL LINEAGE; GENETIC TRANSFECTION; GENETICS; HYPOPHYSIS; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; PHENOTYPE;

MURINAE; MUS MUSCULUS;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CELL AGING; CELL LINEAGE; CELL PROLIFERATION; CLUSTERIN; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA DAMAGE; FORKHEAD TRANSCRIPTION FACTORS; GONADOTROPHS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PHENOTYPE; PITUITARY GLAND; PITUITARY NEOPLASMS; PROMOTER REGIONS, GENETIC; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79953067459     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017924     Document Type: Article

References (64)

1. Kovacs K, Horvath E, Vidal S, (2001) Classification of pituitary adenomas. J Neurooncol 54: 121-127.
2. Fernandez A, Karavitaki N, Wass JA, (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72: 377-382.
3. Melmed S, (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112: 1603-1618.
4. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, et al. (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-353; discussion 341-353.
5. Sharpless NE, DePinho RA, (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113: 160-168.
6. Serrano M, Blasco MA, (2001) Putting the stress on senescence. Curr Opin Cell Biol 13: 748-753.
7. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW, (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
8. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724.
9. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, et al. (2005) Tumour biology: senescence in premalignant tumours. Nature 436: 642.
10. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665.
11. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS, (2010) The essence of senescence. Genes Dev 24: 2463-2479.
12. Jenne DE, Tschopp J, (1989) Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A 86: 7123-7127.
13. Kirszbaum L, Bozas SE, Walker ID, (1992) SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297: 70-76.
14. Trougakos IP, Djeu JY, Gonos ES, Boothman DA, (2009) Advances and challenges in basic and translational research on clusterin. Cancer Res 69: 403-406.
15. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, et al. (2004) Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 64: 7412-7419.
16. Rizzi F, Bettuzzi S, (2010) The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 17: R1-17.
17. Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, et al. (2009) Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene 28: 4344-4352.
18. Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, et al. (2009) Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 101: 663-677.
19. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, et al. (2009) Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol 29: 1558-1564.
20. Sivamurthy N, Stone DH, Logerfo FW, Quist WC, (2001) Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells. J Vasc Surg 34: 716-723.
21. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, et al. (2004) Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res 64: 3126-3136.
22. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, et al. (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761-767.
23. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M, (2008) Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 15: 721-743.
24. Filippella M, Galland F, Kujas M, Young J, Faggiano A, et al. (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65: 536-543.
25. Pei L, Melmed S, (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433-441.
26. Vlotides G, Eigler T, Melmed S, (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165-186.
27. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S, (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317-1321.
28. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, et al. (2005) Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 19: 1383-1391.
29. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572.
30. Zou H, McGarry TJ, Bernal T, Kirschner MW, (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418-422.
31. Wang Z, Yu R, Melmed S, (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 15: 1870-1879.
32. Hsu YH, Liao LJ, Yu CH, Chiang CP, Jhan JR, et al. (2010) Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts. J Biol Chem 285: 22630-22638.
33. Bernal JA, Roche M, Mendez-Vidal C, Espina A, Tortolero M, et al. (2008) Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ 15: 202-212.
34. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, et al. (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A 105: 17498-17503.
35. Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, et al. (2006) FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 20: 2796-2805.
36. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, et al. (2004) Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 6: 168-170.
37. Shen KC, Heng H, Wang Y, Lu S, Liu G, et al. (2005) ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res 65: 8747-8753.
38. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147: 4781-4791.
39. Cuadrado M, Gutierrez-Martinez P, Swat A, Nebreda AR, Fernandez-Capetillo O, (2009) p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. Cancer Res 69: 8726-8732.
40. Collado M, Blasco MA, Serrano M, (2007) Cellular senescence in cancer and aging. Cell 130: 223-233.
41. Ramji DP, Foka P, (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561-575.
42. Nerlov C, (2007) The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 17: 318-324.
43. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP, (2005) C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 24: 1589-1597.
44. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716.
45. Egashira N, Takedoshi S, Takei M, Teramoto A, Osamura R, (2010) Expression of FOXL2 in human normal pituitaries and pituitary adenomas. Modern Pathology pp. 1-9.
46. Swanson SM, Kopchick JJ, (2007) Nuclear localization of growth hormone receptor: another age of discovery for cytokine action? Sci STKE 2007: pe69.
47. Ciccone NA, Xu S, Lacza CT, Carroll RS, Kaiser UB, (2010) Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors. Mol Cell Biol 30: 1028-1040.
48. Kleinberg DL, Wood TL, Furth PA, Lee AV, (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30: 51-74.
49. Goffin V, Binart N, Touraine P, Kelly PA, (2002) Prolactin: the new biology of an old hormone. Annu Rev Physiol 64: 47-67.
50. Janovick JA, Conn PM, (2010) Salt bridge integrates GPCR activation with protein trafficking. Proc Natl Acad Sci U S A 107: 4454-4458.
51. Kuilman T, Peeper DS, (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9: 81-94.
52. Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, et al. (2005) C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 132: 4675-4685.
53. Cao Z, Umek RM, McKnight SL, (1991) Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5: 1538-1552.
54. Rizzi F, Caccamo AE, Belloni L, Bettuzzi S, (2009) Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 219: 314-323.
55. Frost SJ, Simpson DJ, Farrell WE, (2001) Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-beta1-induced expression of p15/INK4B. Mol Cell Endocrinol 176: 29-37.
56. Chi KN, Zoubeidi A, Gleave ME, (2008) Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 17: 1955-1962.
57. Flanagan L, Whyte L, Chatterjee N, Tenniswood M, (2010) Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer 10: 107.
58. Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, et al. (2009) Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 21: 704-711.
59. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, et al. (2005) Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280: 14212-14221.
60. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, et al. (2002) Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21: 4328-4334.
61. Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F, (2009) Clusterin (CLU) and lung cancer. Adv Cancer Res 105: 63-76.
62. Wakefield LM, Roberts AB, (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29.
63. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, et al. (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923.
64. Alarid ET, Windle JJ, Whyte DB, Mellon PL, (1996) Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice. Development 122: 3319-3329.